Gilead Sciences Inc
featured
The ASCO meeting scheduled to begin on May 31st could generate a cornucopia of health care catalysts, said Jim Cramer.
» Read More
More
-
Amgen Inc. rose $2.23 or 2.1 percent, to $108.65. Biogen Idec rose $4.72 or 2.1 percent, to $227.46. Celgene Corp. rose $1.72 or 1.3 percent, to $131.38.
-
Amgen Inc. rose$. 17 or. 2 percent, to $106.89. Biogen Idec rose $9.52 or 4.5 percent, to $222.74. Celgene Corp. rose $2.20 or 1.7 percent, to $129.66.
-
Amgen Inc. rose$. 40 or. 4 percent, to $107.12. Biogen Idec rose $8.36 or 3.9 percent, to $221.58. Celgene Corp. rose $2.97 or 2.3 percent, to $130.43.
-
Amgen Inc. fell$. 32 or. 3 percent, to $106.40. Biogen Idec rose $4.36 or 2.0 percent, to $217.58. Celgene Corp. rose$. 61 or. 5 percent, to $128.07.
-
Amgen Inc. rose $2.16 or 2.1 percent, to $106.72. Biogen Idec rose $3.94 or 1.9 percent, to $213.22. Celgene Corp. rose $4.75 or 3.9 percent, to $127.46.
-
Amgen Inc. rose $1.29 or 1.2 percent, to $105.85. Biogen Idec rose $2.64 or 1.3 percent, to $211.92. Celgene Corp. rose $3.61 or 2.9 percent, to $126.32.
-
Amgen Inc. rose$. 64 or. 6 percent, to $105.20. Biogen Idec rose $1.99 or 1.0 percent, to $211.27. Celgene Corp. rose $2.02 or 1.6 percent, to $124.73.
-
Amgen Inc. fell$. 51 or. 5 percent, to $104.56. Biogen Idec fell $1.43 or. 7 percent, to $209.28. Celgene Corp. fell$. 03 or percent, to $122.71.
-
Amgen Inc. fell$. 09 or. 1 percent, to $104.98. Biogen Idec fell$. 72 or. 3 percent, to $209.99. Celgene Corp. rose$. 53 or. 4 percent, to $123.27.
-
Amgen Inc. fell$. 16 or. 2 percent, to $104.91. Biogen Idec fell$. 38 or. 2 percent, to $210.33. Celgene Corp. fell$. 44 or. 4 percent, to $122.30.
-
Amgen Inc. rose$. 61 or. 6 percent, to $105.07. Biogen Idec fell $1.84 or. 9 percent, to $210.71. Celgene Corp. rose $1.08 or. 9 percent, to $122.74.
-
Amgen Inc. rose$. 14 or. 1 percent, to $104.60. Biogen Idec fell$. 91 or. 4 percent, to $211.64. Celgene Corp. rose$. 81 or. 7 percent, to $122.47.
-
Amgen Inc. rose$. 44 or. 4 percent, to $104.90. Biogen Idec rose $1.23 or. 6 percent, to $213.78. Celgene Corp. rose $1.43 or 1.2 percent, to $123.09.
-
*Bankers expect steady flow of $1 bln to $5 bln pharma deals. The stock valuations of companies like Regeneron Pharmaceuticals Inc, Gilead Sciences Inc, Celgene Corp and Biogen Idec Inc have skyrocketed in the past year or two alone, making it difficult for large pharmaceutical companies to buy them and leaving a trail of dead deals.
-
NEW YORK, May 7- Only half of people in the United States who have ever been infected with hepatitis C get proper testing for the liver-destroying disease, U.S. health officials said on Tuesday.
-
*Risks include high valuation, competitive threats By Ransdell Pierson. TARRYTOWN, N.Y., May 7- Just two years ago, Regeneron Pharmaceuticals was a relatively obscure biotech company in the village of Tarrytown, a picturesque New York suburb better known for "Rip Van Winkle," "The Legend of Sleepy Hollow," and other creations of hometown author Washington Irving.
-
*Shares jump five-fold in two years, market value $26 bln. TARRYTOWN, N.Y., May 7- Just two years ago, Regeneron Pharmaceuticals was a relatively obscure biotech company in the village of Tarrytown, a picturesque New York suburb better known for "Rip Van Winkle," "The Legend of Sleepy Hollow," and other creations of hometown author Washington Irving.
-
NEW YORK, May 3- The Dow and S&P 500 advanced to all-time closing highs on Friday, with major indexes jumping 1 percent after an unexpectedly strong April jobs report eased concerns about an economic slowdown. Bellwether companies, including Chevron Corp, Boeing Co and Johnson& Johnson, reached 52- week highs.
-
Investors are increasingly willing to bet on more economically sensitive sectors like materials, with CNBC's Josh Lipton.